Recommended Tools
AbSeek™ encompasses antibody sequence analysis, structure and function prediction, lead optimization, de novo generation, and visualization, among others, covering all stages of antibody discovery and engineering from screening to optimization for efficient innovation.
Free Tools Limited Time
Sequence Analysis
Function Prediction
Lead Optimization
Structure Prediction
New
Molecule Generation

Features & Advantages
Integration
Combines multiple algorithms to provide a one-stop service that meets all needs in antibody discovery and engineering.
Expertise
Tailors UI and data visualization methods based on the characteristics of antibody data for better suitability.
Advancement
Continuously updates cutting-edge AI algorithms to ensure the platform's timeliness and advancement.
Data Security
Committed to providing users with a secure and reliable data environment, alleviating concerns about data leakage.
News
Cyagen Talk|AI-Powered Antibody Discovery: From HUGO-Ab Mice to Predictive Models
AbSeek™: Intelligent Antibody Computational Platform
2025-03-19
More >>【Frontier Express】Nature Communications | Phase I Clinical Trial of IAP Antagonist ASTX660 Combined with PD-1 Inhibitor for Advanced Solid Tumors
2026-11-03
【Frontier Express】Nature Communications | Ozone-Induced Maternal Immune Activation Drives Offspring IgG-Mediated Anaphylaxis via IgG Glycosylation Modifications
2026-11-03
【Frontier Express】Cell Research | Targeting Necrotic Lipid Release Enhances Immunosurveillance in Glioblastoma
2026-11-02
【Frontier Express】Nature Communications | Feasibility and Mechanism Study of Fecal Microbiota Transplantation for Decolonization of Mucosal Adherent-Invasive Escherichia coli in Crohn's Disease
2026-11-02
【Frontier Express】Nature Communications | Exploratory Phase 2a Mechanistic Trial of SARS-CoV-2-Specific Monoclonal Antibody AER002 in Long COVID
2026-11-01
【Frontier Express】Nature Communications | Neoadjuvant Dual Immune Checkpoint Blockade in Surgically Resectable Recurrent Glioblastoma: A Randomized Window-of-Opportunity Trial
2026-11-01
【Frontier Express】Nature Communications | Phase II Study Results of Ociperlimab Combined with Tislelizumab in Advanced Esophageal Squamous Cell Carcinoma
2026-10-31






